BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27416572)

  • 41. Low density lipoprotein apheresis by membrane differential filtration (cascade filtration).
    Geiss HC; Parhofer KG; Donner MG; Schwandt P
    Ther Apher; 1999 Aug; 3(3):199-202. PubMed ID: 10427615
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption.
    Teruel JL; Lasunción MA; Navarro JF; Carrero P; Ortuño J
    Metabolism; 1995 Jul; 44(7):929-33. PubMed ID: 7616853
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low density lipoprotein-apheresis decreases oxidized low density lipoproteins and monocyte adhesion to endothelial cells.
    Cattin L; Petrucco A; Cazzolato G; Bon GB; Borelli V; Nardon E; Zabucchi G; Fonda M; Bordin P
    ASAIO J; 1997; 43(3):209-13. PubMed ID: 9152493
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis.
    Uauy R; Zwiener RJ; Phillips MJ; Petruska ML; Bilheimer DW
    J Pediatr; 1992 Jun; 120(6):892-8. PubMed ID: 1593349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).
    Matsuzaki M; Hiramori K; Imaizumi T; Kitabatake A; Hishida H; Nomura M; Fujii T; Sakuma I; Fukami K; Honda T; Ogawa H; Yamagishi M
    J Am Coll Cardiol; 2002 Jul; 40(2):220-7. PubMed ID: 12106923
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a).
    Waldmann E; Parhofer KG
    Pathology; 2019 Feb; 51(2):227-232. PubMed ID: 30611543
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies.
    Bambauer R; Schiel R; Latza R
    Ther Apher; 2000 Jun; 4(3):213-7. PubMed ID: 10910023
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-density Lipoprotein Receptor Activities, Lipids, Apolipoprotein, and Clinical Course of Patients with Steroid-resistant Nephrotic Syndrome Treated with Low-density Lipoprotein Apheresis: A Case Series.
    Shima H; Higashiguchi Y; Doi T; Harada M; Okamoto T; Inoue T; Tashiro M; Okada K; Minakuchi J
    Intern Med; 2024 Feb; 63(3):433-438. PubMed ID: 37258157
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.
    Moriarty PM; Parhofer KG; Babirak SP; Cornier MA; Duell PB; Hohenstein B; Leebmann J; Ramlow W; Schettler V; Simha V; Steinhagen-Thiessen E; Thompson PD; Vogt A; von Stritzky B; Du Y; Manvelian G
    Eur Heart J; 2016 Dec; 37(48):3588-3595. PubMed ID: 27572070
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The development of lipoprotein apheresis in Saxony in the last years.
    Kuss SFR; Schatz U; Tselmin S; Fischer S; Julius U
    Ther Apher Dial; 2022 Dec; 26 Suppl 1():53-63. PubMed ID: 36584880
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.
    Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Aukrust P; Retterstøl K; Ose L; Halvorsen B; Holven KB
    J Clin Lipidol; 2013; 7(2):109-16. PubMed ID: 23415429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of a patient with a null low-density lipoprotein receptor mutation: a case report.
    Kolovou GD; Dedoussis GV; Anagnostopoulou KK; Hatzigeorgiou GCh; Salpea KD; Choumerianou DM; Rammos S; Mikhailidis DP; Cokkinos DV
    Angiology; 2006 Dec-2007 Jan; 57(6):729-32. PubMed ID: 17235114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Why an apheresis center should offer more than one lipoprotein apheresis method.
    Julius U; Fischer S; Schatz U; Passauer J; Bornstein S
    Ther Apher Dial; 2013 Apr; 17(2):179-84. PubMed ID: 23551674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia.
    Wu MD; Moccetti F; Brown E; Davidson BP; Atkinson T; Belcik JT; Giraud G; Duell PB; Fazio S; Tavori H; Tsimikas S; Lindner JR
    JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 1):1430-1440. PubMed ID: 29909101
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS).
    Nishimura S; Sekiguchi M; Kano T; Ishiwata S; Nagasaki F; Nishide T; Okimoto T; Kutsumi Y; Kuwabara Y; Takatsu F; Nishikawa H; Daida H; Yamaguchi H
    Atherosclerosis; 1999 Jun; 144(2):409-17. PubMed ID: 10407502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of low-density lipoprotein apheresis on lipoprotein-associated phospholipase A2.
    Moriarty PM; Gibson CA
    Am J Cardiol; 2005 May; 95(10):1246-7. PubMed ID: 15878003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS).
    Tsuchida H; Shigematsu H; Ishimaru S; Iwai T; Akaba N; Umezu S
    Int Angiol; 2006 Sep; 25(3):287-92. PubMed ID: 16878078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of low-density lipoprotein apheresis.
    Ziajka P
    Am J Cardiol; 2005 Aug; 96(4A):67E-69E. PubMed ID: 16098847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Can aggressive lipid lowering using low-density lipoprotein apheresis prevent restenosis after percutaneous transluminal coronary angioplasty in patients with normocholesterolemia?
    Yamashita K; Tasaki H; Tsuda Y; Himeno E; Nakashima Y
    Ther Apher; 1998 Aug; 2(3):210-7. PubMed ID: 10227772
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.
    Lappegård KT; Kjellmo CA; Ljunggren S; Cederbrant K; Marcusson-Ståhl M; Mathisen M; Karlsson H; Hovland A
    Transfus Apher Sci; 2018 Feb; 57(1):91-96. PubMed ID: 29398508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.